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Cancer prevention through weight control—where are we in
2020?
Annie S. Anderson 1, Andrew G. Renehan2, John M. Saxton 3, Joshua Bell4, Janet Cade5, Amanda J. Cross6, Angela King7, Elio Riboli6,
Falko Sniehotta8, Shaun Treweek9, Richard M. Martin 4, On behalf of the UK NIHR Cancer and Nutrition Collaboration
(Population Health Stream)
Growing data from epidemiological studies highlight the association between excess body fat and cancer incidence, but good
indicative evidence demonstrates that intentional weight loss, as well as increasing physical activity, offers much promise as a cost-
effective approach for reducing the cancer burden. However, clear gaps remain in our understanding of how changes in body fat or
levels of physical activity are mechanistically linked to cancer, and the magnitude of their impact on cancer risk. It is important to
investigate the causal link between programmes that successfully achieve short-term modest weight loss followed by weight-loss
maintenance and cancer incidence. The longer-term impact of weight loss and duration of overweight and obesity on risk
reduction also need to be fully considered in trial design. These gaps in knowledge need to be urgently addressed to expedite the
development and implementation of future cancer-control strategies. Comprehensive approaches to trial design, Mendelian
randomisation studies and data-linkage opportunities offer real possibilities to tackle current research gaps. In this paper, we set out
the case for why non-pharmacological weight-management trials are urgently needed to support cancer-risk reduction and help
control the growing global burden of cancer.
British Journal of Cancer https://doi.org/10.1038/s41416-020-01154-3
BACKGROUND
Cancer causes one in six deaths globally and is now overtaking
cardiovascular disease as the leading cause of death across much
of the world.1,2 Currently, tobacco use is the most important single
modifiable risk factor for cancer, but obesity (and its determinants
—high intakes of energy-dense, ultra-processed foods and drinks,
and low levels of physical activity) is becoming increasingly visible
as the second most common cause of cancer. According to the
World Health Organisation (WHO), 1.9 billion adults and over 340
million children and adolescents were living with overweight or
obesity in 2016 (i.e. a body mass index (BMI) > 25 kg/m2) and
these numbers are projected to rise.3 This situation is com-
pounded by global physical activity data suggesting that more
than a quarter of the world’s population is insufficiently active.4
Furthermore, overweight and obesity are occurring at earlier
ages,3 thereby increasing lifetime exposure to associated risks.
Current estimates suggest that overweight and obesity could
overtake smoking as the single biggest cause of cancer in UK
women in around 25 years5 and this premise is also echoed in
international reports.6 Of all new global cancer cases in 2012,
481,000 (or 3.6%) were considered to be attributable to excess
body mass index (BMI).7
The substantial reduction in lung cancer incidence in countries
where public health initiatives have brought about a significant
decrease in smoking indicates the potential of primary cancer
prevention by societal interventions. The implementation of
equitable, population-wide programmes for obesity prevention
and management is eagerly awaited, but sufficient evidence
already currently exists to justify a research focus on intentional
weight loss and cancer-risk-reduction trials. The ultimate objective
of trials with positive results must be to create further leverage for
the development and implementation of policies aimed at
www.nature.com/bjc
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improving the health of the general public—not just the
individuals who have the resources and motivation to participate
in individually focussed weight-loss programmes.
Pharmaceutical options are available to reduce the risk of
obesity-related diabetes and heart disease, but the portfolio of
agents that reduce the risk of developing cancer is very limited.
Considerable amounts of data, including evidence from rando-
mised controlled trials, support the role of aspirin and tamoxifen
in reducing colorectal cancer and breast cancer risk, respectively,
and, although further studies also support a role for other drugs,
such as metformin8,9 and statins,10 in cancer prevention, the
evidence is much weaker. The effectiveness of these pharmaceu-
ticals is relatively modest compared with drugs available for
treating cardiovascular risk factors (hypercholesterolaemia, hyper-
tension and insulin resistance/hyperglycaemia). In addition, the
mechanisms of action of these potential cancer-preventive agents
are not well-established, and their pleiotropic and undesirable side
effects must be considered11 alongside evidence of inverse
associations with mortality.12
Based on the disappointing results of a number of cancer
chemoprevention trials conducted over the past three dec-
ades,13 it is difficult to predict how long it will take to identify
effective drugs with low risk of side effects, and we cannot
afford to wait for pharmacological approaches alone to prevent
cancer risk. The benefit to potentially affected individuals and
their families and the direct and indirect economic implications
of cancer-risk reduction are far-reaching. Addressing cancer
prevention beyond pharmacological solutions has therefore
become a global imperative, and strategies that offer disease
reduction should no longer be ignored. We now have the
evidence to demonstrate that intentional weight loss and
weight management as well as increasing physical activity offer
much promise as cost-effective approaches for reducing the risk
of developing cancer.
OBESITY AND CANCER
The association between obesity and cancer has been reported
and discussed in the literature since the early part of the 20th
century.14 As population rates of overweight and obesity continue
to rise, so will the incidence of common cancers linked to excess
body fat (EBF). As a consequence, escalating costs attributable to
future cancer treatments and the long-term clinical management
of associated comorbidities will place an unrelenting economic
burden on healthcare systems. Action needs to be taken now,
otherwise our failure to seriously address this topic will leave a sad
legacy for the next generation.
Evidence of an association between excess body fatness and
cancer
There is a strong need to address the role of EBF in early life, as it
has been demonstrated to influence the risk of many diseases,
including cancer, in adulthood. Hidayat et al.15 reported associa-
tions between body fatness at a young age and the development
in later life of eight types of cancer. Jensen et al.16 subsequently
reported from the Copenhagen School Health Records Registry
that children who were heavier or gaining more weight than
average at 7–13 years of age (n= 257,623) had a significantly
greater risk of adult colon cancer.
In adulthood, it seems that although the link between obesity
and cancer is becoming more apparent, the significance of weight
gain across adult life remains largely ignored. Not only is weight
gain the pathway to overweight and obesity, but it is also an
independent risk factor for postmenopausal breast cancer risk
(~6% per 5-kg increase in adult weight17), which is probably most
relevant in women with a body mass index (BMI) < 23.4 kg/m2 at
age 20 (who are more likely to gain weight in adulthood than
women with a BMI > 23.4 kg/m2).18
The latest (2018) World Cancer Research Fund (WCRF)/American
Institute for Cancer Research (AICR) expert report17 concluded that
being overweight or obese throughout adulthood increases the
risk of cancers of the mouth, pharynx, larynx, oesophagus
(adenocarcinoma), stomach (cardia), pancreas, gall bladder, liver,
colorectum, breast (postmenopausal), ovary, endometrium, pros-
tate (advanced) and kidney. In addition, a WHO International
Agency for Research on Cancer (IARC) Working Group found
evidence relating EBF to meningioma, thyroid cancer and multiple
myeloma,19 and a hospital-based Danish study of 313,221 patients
reported overweight and obesity being related to haematological
and neurological cancers.20 The reported inverse associations
between physical activity and the risk of cancer at 13 sites,
including some of the most common cancers (breast, lung, bowel
and kidney)21,22 reflect the important role of a physically active
lifestyle in cancer prevention, either via direct mechanisms, such
as improved metabolic control or via its role in the prevention of
adult weight gain.23 Furthermore, studies show that structured
exercise in combination with support for dietary-led weight loss
induces more weight loss than exercise or diet alone, and has the
greatest impact on blood-borne biomarkers associated with
common cancers, including insulin resistance and circulating
levels of sex hormones, leptin and inflammatory markers.24–28
MENDELIAN RANDOMISATION STUDIES
In the absence of randomised clinical trials, evidence for causality
can be strengthened by Mendelian randomisation (MR) studies.29
MR is an instrumental variable method to appraise causality within
observational epidemiology, utilising germline genetic variants
that are robustly associated with potentially modifiable exposures
as proxies (‘instrumental variables’) for the risk factor of interest. As
germline genetic variants tend to be randomly distributed with
respect to most human traits in the general population, MR
studies are less likely to be affected by the sorts of confounding
factors that typically bias observational findings. Additionally, as
germline genotypes cannot be affected by the presence of
disease, the generation of spurious results through reverse
causation is avoided. The objective is to identify modifiable
intervention targets (behavioural or therapeutic) on the inter-
mediate causal pathway between genetic factors and disease.
DNA, although itself unmodifiable, operates through modifiable
pathways, e.g., the proprotein convertase subtilisin/kexin type 1
(PCSK1) gene regulates insulin synthesis; fat mass- and obesity-
associated (FTO) gene promotes food intake. MR exploits this to
identify modifiable exposures that can be used for disease
prevention and therapeutic strategies.
Studies using MR support the influence of higher body fatness
on greater risk of oesophageal, gastric, pancreatic, renal, color-
ectal, endometrial and ovarian cancers.30–33 Indeed, MR analysis
suggests that the obesity-related cancer burden has been
substantially underestimated.34 The volume and location of fat
tissue are strong determinants of insulin resistance and dyslipi-
daemia, and MR studies support strong effects of higher BMI on
higher fasting levels of insulin, glucose, triglycerides, remnant
cholesterol and lower high-density lipoprotein (HDL) cholesterol.35
The adverse metabolic effects of higher fatness are already
evident in late childhood and might worsen with longer time
exposure.36 Higher body fatness also raises systolic and diastolic
blood pressure, and impairs immunity via its association with
elevated pro-inflammatory factors such as interleukin-6.37 Several
of these metabolic traits are associated with an increased risk of
obesity-related cancers, with MR evidence being the strongest for
higher fasting insulin.38
Excess body fatness and breast cancer risk
It is important to note that, from a life-course perspective, higher
body fatness in childhood and adolescence is inversely related to
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the risk of premenopausal breast cancer as well as postmenopau-
sal breast cancer,39 suggesting a long-term protective effect of EBF
on breast cancer risk later in life. Analysis from the cohort-pooling
project papers40 on premenopausal breast cancer confirms that
relative overweight at age 18–24 is associated with a modest
reduction in the risk of premenopausal breast cancer up to the
age of ~50 years, and additional analyses41 indicate that weight
gain from ages 18–24 to 35–44 or to 45–54 years is also inversely
associated with breast cancer overall (e.g., hazard ratio [HR] per 5
kg to ages 45–54: 0.96, 95% confidence interval [CI]: 0.95–0.98)
and with oestrogen-receptor(ER)-positive breast cancer (HR per 5
kg to ages 45–54: 0.96, 95% CI: 0.94–0.98).
Evidence related to MR studies also indicates that a genetically
predicted larger body size at age 10 might protect against breast
cancer in women independent of subsequent body size at a mean
age of 56.5 years.42 These findings suggest that the effect of early-
life body size might persist into later life, regardless of
interventions to influence adult body size. There is also evidence18
that early-life body size exerts a protective effect even when
accounting for age at menarche. A better understanding of the
mechanisms linking childhood body size and timing of puberty
with later breast cancer risk could help inform potential
interventions.
Understanding the crossover effect of obesity with risk
reduction before, and risk increase after, menopause is poorly
characterised, and further work aimed at understanding the
biological mechanisms of how obesity, weight gain and weight
change all impact on breast cancer risk is needed.17 However, the
inverse association of obesity with premenopausal breast cancer
does not alter the overall harmful effects of obesity, given that
weight and weight gain are positively associated with risks of
postmenopausal breast cancer, several other types of cancer and
other adverse health outcomes. In addition, women with obesity
or who have obesity diagnosed with breast cancer are more likely
to have poorer outcomes than leaner women (independent of
their menopausal status).43
WEIGHT MANAGEMENT—EVIDENCE OF PROMISE FROM
OBSERVATIONAL STUDIES
Until 2010, the evidence that intentional weight loss in adulthood
modifies cancer risk was sparse, and mostly relied on self-reported
body weight with relatively short follow-up periods. However,
long-term follow-up data from the Women’s Health Initiative
cohort have since reported that, after a mean follow-up of 11.4
years, women with modest weight loss (≥10 pounds from baseline
weight during the initial 3-year study) had a lower risk of
endometrial cancer compared with those who did not lose
weight.44 This association was the strongest among women with
obesity or who had obesity at baseline. In this cohort, a lower risk
of breast cancer among women who lost weight compared with
women whose weight remained stable was also reported.45
Similarly, the 17-year follow-up of the UK Women’s Cohort Study
has shown a lower risk of postmenopausal breast cancer in those
individuals who lost weight compared to women with stable
weight or those who gained weight.46
The largest study to date on weight change and postmeno-
pausal breast cancer is from the Pooling Project of Prospective
Studies of Diet and Cancer (DCPP),47 which assessed data from
180,885 women aged ≥50 years in whom 6930 invasive breast
cancers were identified at the final follow-up. All women were
surveyed at three points (baseline, first follow-up (mean of 5.2
years) and final follow-up (10 years)). Sustained weight loss was
defined as no less than 2 kg lost between baseline and the first
follow-up, which was not regained by the final follow-up. The
results demonstrated that, compared with women with stable
weight, women with sustained weight loss had a lower risk of
breast cancer than women whose weight remained stable;
moreover, the larger the weight loss, the lower the risk. It is
notable that even modest weight loss (2–4.5 kg) was associated
with a significant reduction in risk (HR 0.87, 95% CI 0.77–0.99). Risk
reduction was specific to women not using postmenopausal
hormone-replacement therapy and the lowest risk was for women
who sustained at least 9 kg of weight loss (who were not taking
hormone therapy).
WEIGHT MANAGEMENT—INDICATIONS FROM INTERVENTION
STUDIES
Evidence for the impact of weight loss on cancer-risk reduction is
also emerging from intervention studies, although no study has
yet been designed (in terms of size and follow-up period)
specifically to assess the effects of weight loss on cancer incidence
or mortality in the general population. Several studies have
evaluated the effect of bariatric surgery on cancer risk, comparing
people with obesity who underwent surgery with that of
individuals in an obesity (non-randomised) control group who
did not. According to a systematic review, bariatric surgery was
reported to be associated with a reduction in the incidence of
overall cancer (pooled odds ratio (POR)= 0.72: 95% CI 0.59–0.87)
and in the incidence of obesity-related cancers (POR= 0.55: 95%
CI 0.31–0.96).48 The cancer-protective effect of bariatric surgery
seems to be more pronounced in women than in men, and most
marked for a reduction in breast cancer risk. It is notable that the
favourable impact of bariatric surgery on cancer risk for adults in
mid- and later life occurs within a relatively short follow-up period
and is independent of physical activity. However, people under-
going bariatric surgery do not necessarily reflect the general
overweight and obese population, and the physiological response
following acute weight loss might in itself produce effects that
might not be matched by weight loss induced through lifestyle
interventions.49 A systematic review of weight-loss trials50
reported a significant reduction in the risk of all-cause mortality,
cardiovascular mortality and cancer mortality. Furthermore, in
2020, the Look Ahead Research Group reported51 that an intensive
lifestyle-intervention trial of 5145 participants, which targeted
weight loss, successfully lowered the incidence of obesity‐related
cancers by 16% in adults with overweight or obesity and type 2
diabetes after a median follow-up of 11 years, highlighting the
potential success of such interventions in cancer-risk reduction.
CONSIDERATIONS IN THE DESIGN OF TRIALS INVESTIGATING
THE INFLUENCE OF WEIGHT LOSS ON CANCER RISK
Irrespective of the mode of weight loss, it is important to
investigate whether or not programmes that successfully achieve
short-term modest weight loss followed by weight-loss main-
tenance confer benefit on cancer incidence. The potential effect of
the latency of risk reduction following weight loss, as well as the
duration of overweight and obesity, need to be fully considered in
trial design. Furthermore, it is important to identify whether or not
the benefits of weight loss are offset by any subsequent regain in
weight. There is much to be learnt from highly successful
diabetes- prevention programmes based on change in caloric
intake and increased physical activity for weight loss,52,53 and it is
particularly notable that in a 15-year follow-up of the Diabetes
Prevention Programme, the incidence of diabetes still remained
lower—by 27%—in the lifestyle-intervention group compared
with the placebo group.54
The influence of physical activity
Whilst reduced caloric intake plays a greater role than physical
activity in weight loss,55 the latter might be particularly important
in weight-loss maintenance.56 However, it is likely that physical
activity confers additional benefits on the reduction of cancer risk,
for example, through modulation of immune-regulatory
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pathways,57 reduced oxidative stress,58 epigenetic changes59 and
reduced telomere attrition60 that may be independent of its
effects on body weight.21 A 2020 MR study using data from the UK
Biobank showed that physical activity is inversely associated with
breast and colon cancer risk, independent of its effect on
adiposity, and the association between physical activity and
cancer incidence at ten sites was shown to be independent of
BMI.61 Furthermore, strength training, which builds skeletal muscle
mass, is inversely associated with the risk of bladder, kidney and
colorectal cancer.62,63 Improvements in insulin sensitivity and
glucose homoeostasis induced by aerobic exercise and/or
strength training64 could reduce the risk of cancers associated
with insulin resistance (and the associated cellular signalling
pathways), including cancers of the colon, liver, pancreas and
endometrium.65
The influence of dietary factors
Similarly, it is important to consider the independent impact of
dietary factors both in terms of macronutrient and micronutrient
composition. Strong evidence exists for a protective role of several
dietary factors in colorectal cancer (whole grains, foods containing
dietary fibre and dairy products) but less so for other cancer
sites.66 Whilst there has been some promising evidence for the
beneficial role of fruit and vegetables in reducing cancer risk, the
overall impact on cancer burden is largely limited to cancers of the
respiratory and upper digestive tract.66,67 Furthermore, enthu-
siasm for micronutrient supplementation to reduce cancer risk has
diminished following a number of randomised control trials that
have produced evidence of an associated increased risk of
cancer.68,69 The lack of the impact of single nutrients/foods on
cancer prevention does not mean that the quality of the diet can
be ignored. Cancers arising from aberrant metabolic pathways are
likely to be influenced by the same nutrients and foods that are
associated with the risk of diabetes,70 and there is some evidence
that healthy dietary patterns (diets that are high in vegetables,
fruit, whole grains, legumes and nuts) are beneficial. In turn, foods
that promote weight gain (e.g., sugar-sweetened beverages),
along with red and processed meats and alcohol, should be
minimised—alcohol consumption is not only a contributor to
caloric intake but also a recognised carcinogen.17
Weight management
Focus on weight management enables a lifestyle pattern
combining diet quality and quantity, alcohol intake and physical
activity to be promoted and tested. Given the tendency for
lifestyle behaviours to cluster/co-occur,71 implementation of
equitable interventions that impact on several key areas of
lifestyle offer considerable scope for reducing the overall disease
burden. Although many unanswered questions exist within
lifestyle interventions, with respect to dose, duration, type (for
physical activity), caloric composition and diet quality (in terms of
food intake), and how best to support long-term adherence, there
is much that we can learn from longer-term lifestyle trials
including those focusing on diabetes prevention. For example,
intervention design no longer focuses on knowledge exchange
alone, but integrates goal-based behavioural interventions, the
use of lifestyle coaches, frequent contact and support and ‘toolbox
strategies' to enable individual tailoring.72 Furthermore, recent
work has highlighted the impact of using behavioural change
techniques to support changes in diet and physical activity.73
WEIGHT-LOSS TRIALS—CHALLENGES AND OPPORTUNITIES
The potential for ‘megatrials’ to answer nutritional questions has
been described by Trepanowski and Ioannidis74 to address
challenges such as selective reporting, small sample size, short
length of follow-up and high costs (trials of non-pharmacological
interventions are generally publicly funded, with relatively low
budgets, which makes large sample sizes and lengthy follow-up
protocols prohibitive). These challenges are common in nutritional
trials (as with other clinical areas), and it is clear that the
methodological rigour of complex dietary behavioural trials needs
to improve. In reality, large randomised controlled trials are likely
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Fig. 1 Expected effects of lowering BMI on cancer risk—how Mendelian Randomisation can guide research. Current estimates from
genetically informed Mendelian randomisation (MR) studies can be used to set expectations for the results of future randomised controlled
trials. A recent meta-analysed MR estimate of BMI for colorectal cancer (from Jarvis et al.76) suggests that a 5 kg/m2 lower BMI would reduce
the risk of developing colorectal cancer by ~20%. This MR estimate reflects lifetime exposure to this relatively lower BMI, and so the
magnitude of reduced colorectal cancer risk in response to short-term BMI reduction is expected to differ.
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management on cancer risk, but will need to be considered
alongside other data sources such as pooled cohort studies,75
triangulated MR approaches (see Fig. 1)76 and network meta-
analysis.77 The science of trial design78 now offers a much clearer
pathway for designing and addressing trial challenges, enabling
researchers to optimise recruitment from populations of interest,
incorporate intervention features (content, implementation, fide-
lity and adherence), comparator groups, adaptive trial design79
and to collect long-term outcomes. The key here is to assess the
body of evidence appropriately by recognising the inherent
weaknesses in the various research designs that contribute to it.
Although three decades of trials of behavioural weight-loss
programmes such as the Diabetes Prevention Programme have
successfully demonstrated a significant reduction in the incidence
of diabetes, weight -loss programmes for cancer prevention have
not received much funding. A 21st- century rationale (as described
by Ballard et al.80) for this lack of investment points to a lack of
good interim biomarkers, the need for prohibitively large sample
sizes, uncertainties about life stage and appropriate ‘dose’ of
intervention, the need to achieve sustained behaviour change and
the apparent desire for genetic discoveries. There are also
concerns that people who attempt and fail to adhere to weight-
loss regimens might experience negative emotional responses
and, indeed, self-blame if a subsequent diagnosis of cancer is
made. However, the past decade has seen a portfolio of weight-
loss regimens combining novel dietary approaches, motivational
technologies and implementation science approaches, which will
help to optimise adherence and provide supportive behaviour
change strategies for weight-loss trials.81,82 Although multicom-
ponent interventions offer significant challenges, such approaches
have been successfully tested in diabetes83 and cognitive
function84 contexts, and are feasible to implement. Modern
wearable technologies to motivate and support behaviour
change, remote objective data collection and record linkage to
routine clinical or registry data for follow-up (of at least a decade)
make some of the difficulties in cancer-prevention trials more
manageable. Furthermore, improvements in trial design, under-
standing of intervention content and dose and knowledge
regarding the provision of effective long-term support for
behaviour change make successful cancer-prevention trials
increasingly plausible. Nevertheless, an important challenge for
primary prevention trial design is the identification of clinically
meaningful short- and longer-term health outcomes. The search
for robust and clinically relevant surrogate markers (e.g., adenoma
recurrence in colorectal cancer, mammographic density and
hormone levels in breast cancer) continues, and such markers
would add considerable confidence to expensive intervention
studies with long-term follow-up. However, it is also important to
note that studies of chemoprevention (e.g., aspirin) that have
cancer development as their primary outcome have been funded,
and lifestyle interventions could do likewise.
Weight management and high-risk populations
One notable population of interest for weight-management trials
includes people who are known to be at a higher risk of
developing cancer, including those with a family history of
colorectal or breast cancer who are already undergoing surveil-
lance procedures. In a large international multicentre trial of
aspirin in patients with Lynch syndrome (hereditary non-polyposis
colorectal cancer), Movahedi et al.85 reported that participants
with obesity were 2.41 times (95% CI, 1.22–4.85) more likely to
develop colorectal cancer than participants with under- and
normal weight, and their risk increased by 7% for each 1 kg/m2
increase in BMI. There is considerable interest in weight manage-
ment in women with a family history of breast cancer, although
the greatest efforts to date have focussed on physical activity
interventions. Gramling et al.86 reported from the Women’s Health
Initiative observational study that healthy lifestyles (i.e., regular
exercise, healthy body weight on the basis of BMI and <7 alcoholic
drinks per week) led to a reduction in the risk of breast cancer in
postmenopausal women, and the degree of this benefit was
similar for women with and without a family history of breast
cancer. A review by Pettapiece-Phillips et al.87 reported evidence
of a protective role of a healthy body size and regular physical
activity among BRCA mutation carriers, notably in adolescence
and early adulthood. A number of feasibility or pilot trials of
weight management have been undertaken in this high-risk
population, including an assessment of the Diabetes Prevention
Programme (with modifications) on breast cancer risk biomar-
kers.88 Intervention studies involving diet and physical activity,89
intermittent energy restriction,90 endurance training and nutrition
counselling on the Mediterranean diet81 in individuals at
increased risk of breast cancer are currently underway. These
developmental studies point to the feasibility of initially ‘testing’
complex intervention trials in high-risk populations and should
provide both rational and relevant platforms for planning
definitive average-risk population-level randomised controlled
trials.
CONCLUSIONS
The need for much greater investment in research into cancer
prevention is beyond question, and yet the current expenditure is
only around 3% of the UK cancer research budget.91 Worldwide,
excess weight is associated with the development of at least 480,000
new cancer cases each year.7 The bulk of current observational
evidence on weight loss and obesity-related cancers suggests that
decreasing body weight, reducing EBF and maintaining losses, by
even relatively modest amounts, can have an impact on future
cancer risk. It is important to note that most obese people who lose
weight will remain in the obese category, but will have reduced
cancer risk by even modest weight loss per se, which should
therefore increase motivation for participating in interventions.
However, clear gaps remain in our understanding of how changes in
body fat or increased levels of physical activity are mechanistically
linked to a decreased incidence of cancer. In addition, under-
standing the impact of different measures of EBF (e.g., body mass
index, central obesity as assessed by waist circumference, bioelec-
trical impedance and DXA) adds to the complexity of identifying
possible solutions.11,12,92 These gaps need to be urgently addressed
to expedite the development and implementation of future cancer-
control strategies.
Well-designed trials, providing robust evidence of impact, are
crucial for efforts to garner funding for weight-management
programmes aimed at reducing cancer risk. To date, trials of
weight management and cancer prevention have almost exclu-
sively been confined to feasibility work. The time has come for an
international commitment to decreasing cancer burden and this
commitment includes the development of large-scale intervention
trials of weight management for primary prevention of obesity-
related cancer—a point also raised in the paper on critical
research gaps and recommendations in colorectal cancer.93 This
need is urgent and the time to act is now!
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